{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:07:04Z","timestamp":1786115224157,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.tjpad.2025.100082","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T04:28:31Z","timestamp":1739766511000},"page":"100082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease"],"prefix":"10.1016","volume":"12","author":[{"given":"Erika N.","family":"Cline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Antwi-Berko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sundell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6734-1131","authenticated-orcid":false,"given":"Maddelyn","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Vanderstichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Kaplow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-4486","authenticated-orcid":false,"given":"Erik","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-5366","authenticated-orcid":false,"given":"Eugeen","family":"Vanmechelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen J.A.","family":"Koel-Simmelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopalan","family":"Sethuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Feaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Siemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"Jerecic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100082_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.848215","article-title":"ACU193: an immunotherapeutic poised to test the amyloid \u03b2 oligomer hypothesis of Alzheimer's disease","volume":"16","author":"Krafft","year":"2022","journal-title":"Front Neurosci"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100082_bib0002","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s12264-022-00985-9","article-title":"Physiological roles of beta-amyloid in regulating synaptic function: implications for AD pathophysiology","volume":"39","author":"Cai","year":"2023","journal-title":"Neurosci Bull"},{"issue":"s1","key":"10.1016\/j.tjpad.2025.100082_bib0003","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The amyloid-beta oligomer hypothesis: beginning of the third decade","volume":"64","author":"Cline","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100082_bib0004","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease","volume":"27","author":"Lacor","year":"2007","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100082_bib0005","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1038\/s41380-022-01589-5","article-title":"Bioactive human Alzheimer brain soluble a\u03b2: pathophysiology and therapeutic opportunities","volume":"27","author":"Li","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100082_bib0006","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100082_bib0007","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ana.21321","article-title":"A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia","volume":"63","author":"Tomiyama","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tjpad.2025.100082_bib0008","article-title":"Role of Abeta in Alzheimer's-related synaptic dysfunction","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100082_bib0009","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.3390\/ijms22126355","article-title":"Neurotoxic soluble amyloid oligomers drive Alzheimer's pathogenesis and represent a clinically validated target for slowing disease progression","volume":"22","author":"Tolar","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"44","key":"10.1016\/j.tjpad.2025.100082_bib0010","doi-asserted-by":"crossref","first-page":"12749","DOI":"10.1021\/bi030029q","article-title":"Self-assembly of Abeta(1-42) into globular neurotoxins","volume":"42","author":"Chromy","year":"2003","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100005","article-title":"INTERCEPT-AD, A phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease","volume":"12","author":"Siemers","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0012","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14283\/jpad.2022.93","article-title":"ACU193, a monoclonal antibody that selectively binds soluble a\u00df oligomers: development rationale, phase 1 trial design, and clinical development plan","volume":"10","author":"Siemers","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100082_bib0013","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100082_bib0014","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup","volume":"38","author":"Jack","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100082_bib0015","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0016","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13195-023-01336-0","article-title":"Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum","volume":"15","author":"Goossens","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100082_bib0017","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","article-title":"Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology","volume":"136","author":"Portelius","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"Pt 11","key":"10.1016\/j.tjpad.2025.100082_bib0018","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/brain\/awv267","article-title":"Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease","volume":"138","author":"Portelius","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.tjpad.2025.100082_bib0019","first-page":"871","article-title":"Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease","volume":"5","author":"Galasko","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100082_bib0020","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/alz.12353","article-title":"Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease","volume":"17","author":"Libiger","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100082_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800105","article-title":"Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer's Disease","volume":"13","author":"Sathe","year":"2019","journal-title":"Proteom Clin Appl"},{"key":"10.1016\/j.tjpad.2025.100082_bib0022","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fnagi.2019.00132","article-title":"Resting-State functional connectivity is associated with cerebrospinal fluid levels of the synaptic protein NPTX2 in non-demented older adults","volume":"11","author":"Soldan","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.tjpad.2025.100082_bib0023","doi-asserted-by":"crossref","first-page":"e23798","DOI":"10.7554\/eLife.23798","article-title":"NPTX2 and cognitive dysfunction in Alzheimer's disease","volume":"6","author":"Xiao","year":"2017","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100082_bib0024","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00415-023-12154-7","article-title":"Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease","volume":"271","author":"Massa","year":"2024","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100082_bib0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02815140","article-title":"Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?","volume":"26","author":"Blennow","year":"1995","journal-title":"Mol Chem Neuropathol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100082_bib0026","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci Lett"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100082_bib0027","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/acn3.50873","article-title":"Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse","volume":"6","author":"Alcolea","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0028","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat Commun"},{"issue":"45","key":"10.1016\/j.tjpad.2025.100082_bib0029","doi-asserted-by":"crossref","first-page":"10191","DOI":"10.1523\/JNEUROSCI.3432-04.2004","article-title":"Synaptic targeting by Alzheimer's-related amyloid \u03b2 oligomers","volume":"24","author":"Lacor","year":"2004","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100082_bib0030","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.celrep.2015.07.044","article-title":"Amyloid-\u03b2 oligomers may impair SNARE-mediated exocytosis by direct binding to syntaxin 1a","volume":"12","author":"Yang","year":"2015","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0031","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1038\/s41598-020-63398-6","article-title":"Oligomeric amyloid-beta induces early and widespread changes to the proteome in human iPSC-derived neurons","volume":"10","author":"Sackmann","year":"2020","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100082_bib0032","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/brain\/awae032","article-title":"Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases","volume":"147","author":"Nilsson","year":"2024","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0033","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13195-023-01212-x","article-title":"Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia","volume":"15","author":"Das","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100082_bib0034","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) Phase 1b study in Alzheimer's disease: rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100082_bib0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0036","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401\u2013a clinical study in Alzheimer's disease with a protofibril selective Abeta antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0037","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J Alzheimers Dis"},{"issue":"44","key":"10.1016\/j.tjpad.2025.100082_bib0038","doi-asserted-by":"crossref","first-page":"18325","DOI":"10.1074\/jbc.M117.801514","article-title":"Mechanisms of recognition of amyloid-beta (Abeta) monomer, oligomer, and fibril by homologous antibodies","volume":"292","author":"Zhao","year":"2017","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100082_bib0039","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2024.0991","article-title":"Downstream biomarker effects of Gantenerumab or Solanezumab in dominantly inherited Alzheimer Disease: The DIAN-TU-001 randomized clinical trial","volume":"81","author":"Wagemann","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-a\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100082_bib0041","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100082_bib0042","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-024-02068-7","article-title":"Analysis of cerebrospinal fluid, plasma \u03b2-amyloid biomarkers, and cognition from a 2-year phase 2 trial evaluating oral ALZ-801\/valiltramiprosate in APOE4 carriers with early Alzheimer's Disease using quantitative systems pharmacology model","volume":"84","author":"Hey","year":"2024","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100082_bib0043","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1002\/alz.14152","article-title":"CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two phase 2 clinical trials in Alzheimer's disease","volume":"20","author":"Lizama","year":"2024","journal-title":"Alzheimers Dement"}],"updated-by":[{"DOI":"10.1016\/j.tjpad.2025.100217","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:52:11Z","timestamp":1785977531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2274580725000263"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100082","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acumen Pharmaceuticals, Inc. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100082"}}